New study aims to unlock secrets of hepatitis d treatment success

NCT ID NCT07313358

Not yet recruiting Knowledge-focused Sponsor: University of Rome Tor Vergata Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This observational study looks at data and samples from 220 people with hepatitis D (HDV) who are already taking the medication bulevirtide. Researchers want to see how well the drug works over time and find markers that predict a good response. The goal is to improve monitoring and care for people with this chronic liver infection.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HDV INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatitis D virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HDV INFECTION

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Heinrich Heine University

Düsseldorf, Germany, 40225, Germany

Contact Phone: •••-•••-•••• Email: •••••@•••••
Università di Milano

Milan, Italy, 20122, Italy

Contact Phone: •••-•••-•••• Email: •••••@•••••